Key Stats for PACS Group Stock
- Price Change: -12.5%
- Current Price: $36.48
- Street Target Price: $44.20
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
PACS Group (PACS) shares are navigating a steep 12.5% short-term decline to $36.48 following its fourth-quarter earnings release, as a slight revenue miss overshadowed a massive beat in profitability.
The post-acute healthcare provider delivered actual revenue of $1.36 billion in the fourth quarter, missing analyst estimates of $1.38 billion by exactly 1.8%.
However, management highlighted record operational efficiency, delivering an Actual Adjusted EPS of $0.57, which outperformed the Street estimate by a staggering 26.6%.
CEO Jason Murray detailed exactly why the company’s “locally led, centrally supported” operating model is driving record full-year performance.
Murray stated verbatim: “Today marks a very important milestone for PACS as we report our fourth quarter and full year 2025 results… We’re especially proud to reach this point while delivering record performance.”
The company ended 2025 with an exceptionally strong balance sheet, maintaining a net leverage ratio of approximately 0.3x even after completing eight strategic acquisitions during the year.
See analysts’ growth forecasts and price targets for PACS Group stock (It’s free!) >>>
Is PACS Group Undervalued Today?
Aggregated analyst data indicate that the market is overreacting to the minor top-line miss while heavily underestimating the compounding value of the company’s high-margin mature facilities.
The consensus Street target price of $44.20 represents an attractive 21.2% potential return from the current $36.48 baseline price.
The company is deliberately expanding its footprint in high-density markets, recently announcing the acquisition of three additional facilities in Alaska and Idaho in January 2026.
Executive Vice Chairman Mark Hancock explained exactly how the company’s capital structure is positioned for sustained inorganic growth.
Hancock stated verbatim: “We ended the year with a net leverage of approximately 0.3x… this conservative balance sheet provides meaningful financial flexibility and positions us to be opportunistic.”
Read the full PACS Group Transcript on TIKR to see the 2026 expansion roadmap >>>
Valuation Deep Dive
The TIKR Analyst Breakdown identifies PACS Group as a dominant consolidator in the fragmented skilled nursing landscape, successfully transitioning into a national healthcare leader.
- Street Target Price: $44.20
- Current Price: $36.48
- 1D Stock Reaction: -12.46%
The Mature Facility Cash Cow: PACS is aggressively positioning itself to own the aging population demographic shift. Its mature facilities delivered an exceptional 94.9% occupancy rate in 2025, significantly higher than the industry average.
Quality Moat and Regulatory Execution: The commercial engine is operating at peak clinical quality. Management highlighted that 73.4% of its skilled nursing portfolio is currently rated 4 or 5 stars by CMS, providing a structural advantage in securing hospital referrals.
Conclusion: A revitalized healthcare giant successfully leveraging its low leverage and high quality ratings to dominate the post-acute care market. PACS Group offers a steady path to long-term appreciation. The path to the $44.20 target is paved by record EPS execution, a fortress balance sheet, and a robust M&A pipeline.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.rime” potential? [Click here to see the full Valuation Model for Intuitive Machines.]
Should You Invest in PACS Group?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up PACS Group, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track PACS Group alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
[Analyze PACS Group on TIKR Free →]
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
